• Mai Kimura, Yuichi Tamura, Christophe Guignabert, Makoto Takei, Kenjiro Kosaki, Nobuhiro Tanabe, Koichiro Tatsumi, Tsutomu Saji, Toru Satoh, Masaharu Kataoka, Shigeo Kamitsuji, Naoyuki Kamatani, Raphaël Thuillet, Ly Tu, Marc Humbert, Keiichi Fukuda, and Motoaki Sano.
• Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
• Oncotarget. 2017 Sep 26; 8 (43): 74917-74926.

AbstractPulmonary arterial hypertension (PAH) is a lethal disease that often affects the young. Although Bone Morphogenetic Protein Receptor Type 2 gene (BMPR2) mutations are related with idiopathic and heritable PAH, the low penetrance and variable expressivity in PAH suggest the existence of other genetic and/or environmental factors. In this study, we aimed to identify novel genetic factors associated with PAH, irrespective of BMPR2 mutation. We performed genome-wide association study (GWAS) in a Japanese population comprising 44 individuals with idiopathic and heritable PAH, and 2,993 controls. Seven loci identified in the genome-wide study were submitted to the validation study, and a novel susceptibility locus, PDE1A|DNAJC10, was identified that maps to 2q32.1 (rs71427857, P = 7.9 × 10-9, odds ratio in the validation study = 5.18; 95% CI 1.86 - 14.42). We also found the augmentation of PDE1A protein in distal remodeled pulmonary artery walls in idiopathic PAH patients. Given that phosphodiesterase 5 inhibitors are effective for the treatment of idiopathic and heritable PAH, our findings suggest that PDE1A could be a novel therapeutic target of PAH.

3 keywords...

hide…